General Information of the Protein
Protein ID
PT00954
Protein Name
Receptor-interacting serine/threonine-protein kinase 1
Secondarily
Protein Name
Cell death protein RIP
Receptor-interacting protein 1
Gene Name
RIPK1
Secondarily
Gene Name
RIP
RIP1
Sequence
MQPDMSLNVIKMKSSDFLESAELDSGGFGKVSLCFHRTQGLMIMKTVYKGPNCIEHNEALLEEAKMMNRLRHSRVVKLLGVIIEEGKYSLVMEYMEKGNLMHVLKAEMSTPLSVKGRIILEIIEGMCYLHGKGVIHKDLKPENILVDNDFHIKIADLGLASFKMWSKLNNEEHNELREVDGTAKKNGGTLYYMAPEHLNDVNAKPTEKSDVYSFAVVLWAIFANKEPYENAICEQQLIMCIKSGNRPDVDDITEYCPREIISLMKLCWEANPEARPTFPGIEEKFRPFYLSQLEESVEEDVKSLKKEYSNENAVVKRMQSLQLDCVAVPSSRSNSATEQPGSLHSSQGLGMGPVEESWFAPSLEHPQEENEPSLQSKLQDEANYHLYGSRMDRQTKQQPRQNVAYNREEERRRRVSHDPFAQQRPYENFQNTEGKGTAYSSAASHGNAVHQPSGLTSQPQVLYQNNGLYSSHGFGTRPLDPGTAGPRVWYRPIPSHMPSLHNIPVPETNYLGNTPTMPFSSLPPTDESIKYTIYNSTGIQIGAYNYMEIGGTSSSLLDSTNTNFKEEPAAKYQAIFDNTTSLTDKHLDPIRENLGKHWKNCARKLGFTQSQIDEIDHDYERDGLKEKVYQMLQKWVMREGIKGATVGKLAQALHQCSRIDLLSSLIYVSQN
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Kinase
>
Protein Kinase
>
TKL protein kinase group
>
TKL protein kinase RIPK family
Function
Serine-threonine kinase which is a key regulator of TNF-mediated apoptosis, necroptosis and inflammatory pathways (PubMed:32657447, PubMed:31827280, PubMed:31827281, PubMed:17703191, PubMed:24144979). Exhibits kinase activity-dependent functions that regulate cell death and kinase-independent scaffold functions regulating inflammatory signaling and cell survival (PubMed:11101870, PubMed:19524512, PubMed:19524513, PubMed:29440439, PubMed:30988283). Has kinase-independent scaffold functions: upon binding of TNF to TNFR1, RIPK1 is recruited to the TNF-R1 signaling complex (TNF-RSC also known as complex I) where it acts as a scaffold protein promoting cell survival, in part, by activating the canonical NF-kappa-B pathway (By similarity). Kinase activity is essential to regulate necroptosis and apoptosis, two parallel forms of cell death: upon activation of its protein kinase activity, regulates assembly of two death-inducing complexes, namely complex IIa (RIPK1-FADD-CASP8), which drives apoptosis, and the complex IIb (RIPK1-RIPK3-MLKL), which drives necroptosis (By similarity). RIPK1 is required to limit CASP8-dependent TNFR1-induced apoptosis (By similarity). In normal conditions, RIPK1 acts as an inhibitor of RIPK3-dependent necroptosis, a process mediated by RIPK3 component of complex IIb, which catalyzes phosphorylation of MLKL upon induction by ZBP1 (PubMed:19524512, PubMed:19524513, PubMed:29440439, PubMed:30988283). Inhibits RIPK3-mediated necroptosis via FADD-mediated recruitment of CASP8, which cleaves RIPK1 and limits TNF-induced necroptosis (PubMed:19524512, PubMed:19524513, PubMed:29440439, PubMed:30988283). Required to inhibit apoptosis and necroptosis during embryonic development: acts by preventing the interaction of TRADD with FADD thereby limiting aberrant activation of CASP8 (By similarity). In addition to apoptosis and necroptosis, also involved in inflammatory response by promoting transcriptional production of pro-inflammatory cytokines, such as interleukin-6 (IL6) (PubMed:31827280, PubMed:31827281). Phosphorylates RIPK3: RIPK1 and RIPK3 undergo reciprocal auto- and trans-phosphorylation (PubMed:19524513). Phosphorylates DAB2IP at 'Ser-728' in a TNF-alpha-dependent manner, and thereby activates the MAP3K5-JNK apoptotic cascade (PubMed:17389591, PubMed:15310755). Required for ZBP1-induced NF-kappa-B activation in response to DNA damage (By similarity).
    Show/Hide
Uniprot ID
Primary ID:
Q13546

Secondarily ID:
A0AV89
B2RAG1
B4E3F9
Q13180
Q59H33
    Show/Hide
Ensembl ID
ENSG00000137275
HGNC ID
HGNC:10019
Subcellular Location
Cytoplasm
Cell membrane
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000025 , HEK-293T
Compound ID Compound Name Compound Formula
CP0066612
5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,2-oxazole-3-carboxamide
   Show/Hide
C21H19N3O4
 1
1
IC50 = 2.8 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0198699
5-benzyl-N-[(3S)-1-methyl-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]-1,2-oxazole-3-carboxamide
   Show/Hide
C22H21N3O3
 1
1 IC50 = 0.2 nM
CP0244579
5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide
   Show/Hide
C20H19N5O3
 6
1 IC50 = 0.4 nM
2 IC50 = 0.5 nM
3 IC50 = 1 nM
4 IC50 = 1.6 nM
5 IC50 = 2 nM
6 IC50 = 33 nM
CP0135419
5-benzyl-N-[(3S)-7,9-difluoro-2-oxo-1,3,4,5-tetrahydro-1-benzazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide
   Show/Hide
C20H17F2N5O2
 4
1 IC50 = 0.4 nM
2 IC50 = 0.5 nM
3 IC50 = 1.6 nM
4 IC50 = 19.95 nM
CP0066615
5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1H-1,5-benzodiazepin-3-yl]-1,2-oxazole-3-carboxamide
   Show/Hide
C21H20N4O3
 1
1 IC50 = 0.79 nM
CP0066616
5-benzyl-N-[(3R)-5-methyl-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl]-1,2-oxazole-3-carboxamide
   Show/Hide
C21H19N3O3S
 1
1 IC50 = 0.94 nM
CP0432286
1-[3-[5-(3-aminophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]phenyl]-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea
   Show/Hide
C27H19F4N5O
 2
1 IC50 = 1.3 nM
2 IC50 = 32 nM
CP0066612
5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,2-oxazole-3-carboxamide
   Show/Hide
C21H19N3O4
 3
1 IC50 = 1.6 nM
2 IC50 = 10 nM
3 Ki = 0.8 nM
CP0020525
2,2-dimethyl-1-[(3S)-3-phenyl-3,4-dihydropyrazol-2-yl]propan-1-one
   Show/Hide
C14H18N2O
 2
1 IC50 = 1.6 nM
2 IC50 = 16 nM
CP0174972
N-[(3S)-4-oxo-3,5-dihydro-2H-1,5-benzoxazepin-3-yl]-3-phenoxybenzamide
   Show/Hide
C22H18N2O4
 2
1 IC50 = 7.9 nM
2 IC50 = 40 nM
CP0489559
6-[4-[(3S)-3-(3,5-difluorophenyl)-3,4-dihydropyrazole-2-carbonyl]piperidin-1-yl]pyrimidine-4-carbonitrile
   Show/Hide
C20H18F2N6O
 1
1 IC50 = 10 nM
CP0246542
N-benzyl-N-hydroxy-2,2-dimethylbutanamide
   Show/Hide
C13H19NO2
 2
1 IC50 = 13 nM
2 IC50 = 298 nM
CP0018963
3-(4-{4-aminofuro[2,3-d]pyrimidin-5-yl}phenyl)-1-[2-fluoro-5-(trifluoromethyl)phenyl]urea
   Show/Hide
C20H13F4N5O2
 1
1 IC50 = 13 nM
CP0392870
1-(3-methylphenyl)-3-[3-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl]urea
   Show/Hide
C27H22N4O
 2
1 IC50 = 13 nM
2 IC50 = 20 nM
CP0061196
5-benzyl-N-[(3S)-4-oxo-3,5-dihydro-2H-1,5-benzoxazepin-3-yl]-1,2-oxazole-3-carboxamide
   Show/Hide
C20H17N3O4
 2
1 IC50 = 16 nM
2 IC50 = 32 nM
CP0237070
1-[4-(1-aminoisoquinolin-5-yl)phenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea
   Show/Hide
C23H23N5O2
 1
1 IC50 = 25 nM
CP0236763
(5R)-5-[(7-chloro-1H-indol-3-yl)methyl]-3-methyl-2,4-Imidazolidinedione, 11
   Show/Hide
C13H12ClN3O2
 3
1 IC50 = 200 nM
2 IC50 = 320 nM
3 IC50 = 630 nM
CP0556856
N-[(3S)-4-oxo-3,5-dihydro-2H-1,5-benzoxazepin-3-yl]-5-pentyl-1H-pyrazole-3-carboxamide
   Show/Hide
C18H22N4O3
 1
1 IC50 = 320 nM
CP0072202
5-(1H-indol-3-ylmethyl)-3-methyl-2-thioxo-4-Imidazolidinone, Nec-1
   Show/Hide
C13H13N3OS
 2
1 IC50 = 760 nM
2 IC50 = 1139 nM
CP0352614
5-benzyl-N-[(3R)-4-oxo-3,5-dihydro-2H-1,5-benzoxazepin-3-yl]-1,2-oxazole-3-carboxamide
   Show/Hide
C20H17N3O4
 1
1 IC50 > 10000 nM
CP0518448
2,2-dimethyl-1-[(3R)-3-phenyl-3,4-dihydropyrazol-2-yl]propan-1-one
   Show/Hide
C14H18N2O
 1
1 IC50 > 10000 nM
CP0569007
CHEMBL5177284
   Show/Hide
C19H22FN5
 1
1 IC50 > 30000 nM
CP0438481
4-(1H-pyrrolo[2,3-b]pyridin-2-yl)phenol
   Show/Hide
C13H10N2O
 1
1 Kd = 218 nM
CP0038097
5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide
   Show/Hide
C21H23N7O2S
 1
1 Kd = 260 nM
Clinical Information about the Protein
Target 1 ( Receptor-interacting protein 1 (RIPK1) )
Target Type Clinical trial Target
Disease 4 Target-related Diseases  4
1 Plaque psoriasis [ICD-11: EA90.0]
2 Pancreatic cancer [ICD-11: 2C10]
3 Inflammation [ICD-11: 1A00-CA43.1]
4 Non-alcoholic fatty liver disease [ICD-11: DB92]
Clinical Trial Drug(s) 2 Clinical Trial Drugs  2
1 GSK2982772 Phase 2
Plaque psoriasis
2 GSK3145095 Phase 1/2
Pancreatic cancer
Investigative Drug(s) 1 Investigative Drug  1
1 RIPA-56 Investigative
Non-alcoholic fatty liver disease
Preclinical Drug(s) 1 Preclinical Drug  1
1 GNE684 Preclinical
Inflammation
Target 2 ( HUMAN receptor-interacting protein 1 (RIPK1) )
Target Type Unknown Type Target